Ikena Oncology, Inc. and Inmagene Biopharmaceuticals have announced the appointment of Kristin Yarema, Ph.D., as the Chief Executive Officer of their newly merged company, ImageneBio, Inc. The merger is expected to close by the end of July 2025. Dr. Yarema brings extensive leadership experience in human therapeutics, having previously served as CEO of Poseida Therapeutics, Inc. The combined company will focus on developing treatments for autoimmune and inflammatory diseases and will trade on Nasdaq under the ticker symbol "IMA".
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.